CSL LTD SPON.ADR 2(CSJA) News

Date	Title
Feb 20	CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
Jan 10	Is CSL Limited (ASX:CSL) Trading At A 30% Discount?